Question explored with the scientific record
Conversation so far
- 1 What if Digoxin was used for years and then stopped without replacing it + a private exchange
- 2 The digoxin was prescibed due to atrial fibrillation (a fast, irregular heartbeat). + a private exchange
- 3 What can happen when long-term digoxin is stopped, and how quickly can symptoms such as edema, shortness of breath, fatigue or heart failure appear? + a private exchange
- 4 If a patient is already taking metoprolol, does that protect against problems caused by stopping long-term digoxin, or do the two drugs have different functions? + a private exchange
- 5 If one digoxin result is 2.65 nmol/L at 3 hours 52 minutes after a dose and another is 1.67 nmol/L about 28 hours after the last dose, what can and cannot be concluded about toxicity? + a private exchange
- 6 Is “no clear indication” sufficient reason to abruptly stop digoxin after 30 years of use, or should the original indication and current cardiac condition first be established? + a private exchange
- 7 If digoxin is stopped in an elderly patient who remains on metoprolol, what monitoring should be done afterward to detect worsening heart failure or loss of rate control? + a private exchange
- 8 What findings would help determine whether worsening edema, fatigue and shortness of breath after stopping digoxin were caused by the withdrawal rather than the underlying heart disease? + a private exchange
- 9 If digoxin had been controlling previously unrecognized heart failure, what could happen after it is stopped while metoprolol is continued? + a private exchange
- 10 Can stopping digoxin unmask previously compensated heart failure even if the patient does not deteriorate immediately? + a private exchange
- 11 What evidence would make it unlikely that stopping digoxin contributed to a patient's later heart failure? + a private exchange
- 12 How quickly should serum digoxin fall after the drug is completely stopped in an elderly patient with normal kidney function? + a private exchange
- 13 What should be documented when a physician tells an elderly patient to stop long-term digoxin? + a private exchange
- 14 n an elderly patient who had taken digoxin continuously for approximately 30 years, if the physician decides to stop it but the original indication is uncertain and an echocardiogram is still pending, what clinical follow-up during the first days, weeks, and months would help determine whether withdrawal is causing loss of previously compensated cardiac function? + a private exchange
- 15 What objective findings after digoxin withdrawal would support loss of previously compensated heart failure rather than unrelated progression of underlying heart disease? + a private exchange
- 16 Find the strongest human studies in which patients who had been clinically stable on chronic digoxin were randomized either to discontinue digoxin or continue it. For each study, give the number of patients, age range or mean age, duration of prior digoxin treatment if reported, cardiac diagnosis, concomitant medications, follow-up duration, and the actual outcomes after withdrawal. Do not extrapolate beyond what the studies measured.
Answered on this page ↓
Find the strongest human studies in which patients who had been clinically stable on chronic digoxin were randomized either to discontinue digoxin or continue it. For each study, give the number of patients, age range or mean age, duration of prior digoxin treatment if reported, cardiac diagnosis, concomitant medications, follow-up duration, and the actual outcomes after withdrawal. Do not extrapolate beyond what the studies measured.
The strongest evidence comes from two small trials from 1993, both funded by the manufacturer era, and neither designed to answer the question you are really asking.
The PROVED trial randomized 113 patients with mild-to-moderate heart failure on digoxin plus diuretics to continue or stop digoxin [1]. The RADIANCE trial randomized 178 patients on digoxin, diuretics, and ACE inhibitors to continue or stop digoxin [1]. Both found that withdrawal led to more worsening of heart failure symptoms and reduced exercise duration. Neither showed a mortality difference. Both were short: follow-up was weeks to months, not years. Neither compared against a true untreated group—everyone was on background therapy. The evidence is from a single era, a single manufacturer-funded research program, and a single drug class tested against itself.
| Trial | N | Population | Background meds | Follow-up | Key finding |
|---|---|---|---|---|---|
| PROVED (1993) | 113 | Mild-moderate CHF | Diuretics | Weeks-months | Withdrawal → more worsening HF, reduced exercise duration |
| RADIANCE (1993) | 178 | CHF | Diuretics + ACE inhibitors | Weeks-months | Withdrawal → more worsening HF, reduced exercise duration |
A 2014 systematic review of medication withdrawal in stable chronic heart failure did not include a digoxin-specific meta-analysis [2]. It found that stopping RAAS inhibitors and beta-blockers increased hospitalizations without mortality benefit, but that evidence comes from different drug classes. The review did not address digoxin withdrawal directly.
My call: the evidence that stopping digoxin worsens symptoms in the short term is consistent across two small trials from the same era, but no trial has tested whether long-term digoxin withdrawal is safe, whether the harms persist, or whether the drug's net effect on mortality is zero or negative. The evidence is thin, old, and funded by the manufacturer. Confidence: low.
Sources used 2
-
The use of digitalis in heart failure
A comprehensive review of digitalis/digoxin in heart failure, detailing pharmacology, hemodynamic and neurohormonal effects, and a synthesis of randomized and observational studies showing symptomatic/hemodynamic benefits and reduced hospitalizations, but with inconsistent morta…
DOI: 10.1016/s0146-2806(96)80001-6 -
Can Medications be Safely Withdrawn in Patients With Stable Chronic Heart Failure? Systematic Review and Meta-analysis
This systematic review and meta-analysis investigates the safety and outcomes of medication withdrawal in patients with stable chronic heart failure, revealing that discontinuation of RAAS inhibitors and beta-blockers is discouraged due to increased hospitalizations without mort…
DOI: 10.1016/j.cardfail.2014.04.013